Advertisement

Renal Disorders in Liver Disease

  • Murray Epstein

Abstract

Cirrhosis of the liver is a common clinical condition that afflicts a major portion of the population of the United States. The importance of this disease is underscored by reports indicating that the age-adjusted death rate (14.8 deaths/100,000 population) for cirrhosis has increased by 67% between 1950 and 1969, ranking it as the tenth leading cause of death in the United States (1). At least 600,000 Americans (3.6 of every 1000 adults in the U.S. population) are estimated to have cirrhosis, but many think this figure greatly underestimates the prevalence of this disorder. Since most patients with cirrhosis have ascites and edema during the course of the disease, the impact of ascites on health care is enormous. Included among the numerous complications that affect the course of cirrhosis are derangements of renal function. Since several studies have indicated that renal failure occurs in 50–75% of patients dying of cirrhosis (2, 3), extrapolation of these data underscore the clinical importance of this complication.

Keywords

Cirrhotic Patient Pulmonary Capillary Wedge Pressure Ascitic Fluid Sodium Retention Hepatorenal Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mortality Trends for Leading Causes of Death, United States — 1950–1969. Vital and Health Statistics, Ser. 20:26, p 4. DHEW publication (HRA) 74–1853.Google Scholar
  2. 2.
    Clermont RJ, Vlahcevic ZR, Chalmers TC, Adham NF, Curtis GW, Morrison RS: Intravenous therapy of massive ascites in patients with cirrhosis II. Long-term effects on survival and frequency of renal failure. Gastroenterology 53:220–228, 1967.Google Scholar
  3. 3.
    Epstein M: Treatment of refractory ascites. N Engl J Med 321:1675–1677, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    Brown J: The philosophical transaction of the Royal Society, Vol. III. 1685, p 248.Google Scholar
  5. 5.
    Epstein M: Renal sodium handling cirrhosis. In: M Epstein, ed, The Kidney in Liver Disease, 3rd ed. Williams and Wilkins, Baltimore, pp 3–30, 1988.Google Scholar
  6. 6.
    Epstein M: The sodium retention of cirrhosis: A reappraisal. Hepatology 6:312–315, 1986.PubMedCrossRefGoogle Scholar
  7. 7.
    Klinger EL Jr, Vaamonde CA, Vaamonde LS, Lancestremere RG, Morosi HJ, Frisch E, Papper S: Renal function changes in cirrhosis of the liver. Arch Intern Med 126:1010–1015, 1970.CrossRefGoogle Scholar
  8. 8.
    Gabuzda GJ: Cirrhosis, ascites, and edema. Clinical course related to management. Gastroenterology 58:546–553,1970.Google Scholar
  9. 9.
    Epstein M: Renal effects of head-out water immersion in man: Implications for an understanding of volume homeostasis. Physiol Rev 58:529–581, 1978.PubMedGoogle Scholar
  10. 10.
    Epstein M: Renal sodium handling in cirrhosis: A reappraisal. Nephron 23:211–217, 1979.PubMedCrossRefGoogle Scholar
  11. 11.
    Lieberman FL, Denison EK, Reynolds TB: The relationship of plasma volume, portal hypertension, ascites and renal sodium retention in cirrhosis: The overflow theory of ascites formation. Ann NY Acad Sci 170:202–212, 1970.CrossRefGoogle Scholar
  12. 12.
    Lieberman FL, Ito S, Reynolds TB: Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR) and a fall in GFR during drug-induced diuresis. J Clin Invest 48:975–981, 1969.PubMedCrossRefGoogle Scholar
  13. 13.
    Levy M, Wexler MJ, McCaffrey C: Sodium retention in dogs with experimental cirrhosis following removal of ascites by continuous peritoneovenous shunting. J Lab Clin Med 94:933–946, 1979.PubMedGoogle Scholar
  14. 14.
    Chaimovitz C, Szylman P, Alroy G, Better OS: Mechanism of increased renal tubular sodium reabsorption in cirrhosis. Am J Med 52:198–202, 1972.PubMedCrossRefGoogle Scholar
  15. 15.
    Boyer TD, Zia P, Reynolds TB: Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 77:215–222, 1979.PubMedGoogle Scholar
  16. 16.
    Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R: Prostaglandins: Modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol and Metab 48:895–900, 1979.CrossRefGoogle Scholar
  17. 17.
    Epstein M, Lifschitz M: Renal eicosanoids as determinants of renal function in liver disease. Hepatology 7:1359–1367, 1987.PubMedCrossRefGoogle Scholar
  18. 18.
    Conn HO: Diuresis of ascites: Fraught with or free from hazard. Gastroenterology 73:619–621, 1977.PubMedGoogle Scholar
  19. 19.
    Conn HO, Fessel JM: Spontaneous bacterial peritonitis in cirrhosis. Variations on a theme. Medicine 50: 161–197, 1971.PubMedCrossRefGoogle Scholar
  20. 20.
    Sherlock S: Ascites formation in cirrhosis and its management. Scand J Gastroenterol 7 (Suppl):9–15, 1970.Google Scholar
  21. 21.
    Naranjo CA, Pontigo E, Valdenegro C, Gonzalez G, Ruiz J, Busio V: Furosemide-induced adverse reactions in cirrhosis of the liver. Clin Pharm Therap 25:154–160, 1979.PubMedGoogle Scholar
  22. 22.
    Spino M, Sellers EM, Kaplan HL, Stapleton C, MacLeod SM: Adverse biochemical and clinical consequences of furosemide administration. Can Med Assoc J 118:1513–1518, 1978.PubMedGoogle Scholar
  23. 23.
    Brater DC: Pharmacokinetics and pharmacodynamics in cirrhosis. In: M Epstein, ed, The Kidney in Liver Disease, 3rd ed. Williams & Wilkins, Baltimore, pp 551–571, 1988.Google Scholar
  24. 24.
    Berger BE, Warnock DG: Clinical uses and mechanisms of action of diuretic agents. In: BM Brenner, FC Rector, eds, The Kidney. WB Saunders, Philadelphia, pp 433–455, 1986.Google Scholar
  25. 25.
    Epstein M: Diuretic therapy in liver disease. In: M Epstein, ed, The Kidney in Liver Disease, 3rd ed. Williams & Wilkins, Baltimore, pp 537–550, 1988.Google Scholar
  26. 26.
    Shear L, Ching S, Gabuzda GJ: Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 282:1391–1396, 1970.PubMedCrossRefGoogle Scholar
  27. 27.
    Gabuzda GJ, Hall PW III: Relation of potassium depletion to renal ammonium metabolism and hepatic coma. Medicine 45:481–490, 1966.CrossRefGoogle Scholar
  28. 28.
    Arroyo V, Gines P, Planas R, Panes J, Rodes J: Paracentesis in the management of cirrhotics with ascites. In: M Epstein, ed, The Kidney in Liver Disease, 3rd ed. Williams & Wilkins, Baltimore, pp 578–592, 1988.Google Scholar
  29. 29.
    Kao HW, Rakov NE, Savage E, Reynolds TB: The effect of large volume paracentesis on plasma volume — A cause of hypovolemia? Hepatology 5:403–407, 1985.PubMedCrossRefGoogle Scholar
  30. 30.
    Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: The importance of peripheral edema. Gastroenterology 90:1827–1833, 1986.PubMedGoogle Scholar
  31. 31.
    Simon DM, McCain JR, Bonkovsky HL, Wells JO, Hartle DK, Galambos JT: Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function. Hepatology 7:423–429, 1987.PubMedCrossRefGoogle Scholar
  32. 32.
    Flint A: A clinical report of hydro-peritoneum, based on an analysis of forty-six cases. Am J Med Sci 45:306–339, 1863.CrossRefGoogle Scholar
  33. 33.
    Eknoyan G, Martinez-Maldonado M, Yuim JJ, Suki WN: Combined ascitic fluid infusion and furosemide in the management of ascites. N Engl J Med 282:713–717, 1970.PubMedCrossRefGoogle Scholar
  34. 34.
    Wilkinson SP, Davidson AR, Henderson J, Williams R: Ascites reinfusion using the Rhodiascit apparatus: Clinical experience and coagulation abnormalities. Postgrad Med 51:585–587, 1975.Google Scholar
  35. 35.
    Inoue N, Yamazaki Z, Oda T, Sugiura M, Wada T: Treatment of intractable ascites by continuous reinfusion of the sterilized, cell-free and concentrated ascitic fluid. Trans Am Soc Artif Intern Organs 23:699–702, 1977.PubMedGoogle Scholar
  36. 36.
    LeVeen HH, Christoudias G, Ip M, Luft R, Falk G, Grosberg S: Peritoneo-venous shunting for ascites. Ann Surg 180:580–590, 1974.CrossRefGoogle Scholar
  37. 37.
    Epstein M: Role of the peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. In: M Epstein, ed, The Kidney in Liver Disease, 3rd ed. Baltimore, Williams & Wilkins, pp 593–612, 1988.Google Scholar
  38. 38.
    Epstein M: The LeVeen shunt for ascites and hepatorenal syndrome. N Engl J Med 302:628–630, 1980.PubMedCrossRefGoogle Scholar
  39. 39.
    Greenlee HB, Stanley MM, Reinhardt GF: Long term results in 52 alcoholic cirrhotics with intractable ascites treated with peritoneovenous shunts (LeVeen): 24–64 months follow-up. Arch Surg 116:518–526, 1981.PubMedGoogle Scholar
  40. 40.
    Smadja C, Franco D: The LeVeen shunt in the elective treatment of intractable ascites in cirrhosis. A prospective study on 140 patients. Ann Surg 201:488–493, 1985.PubMedCrossRefGoogle Scholar
  41. 41.
    Kostroff KM, Ross DW, Davis JM: Peritoneo-venous shunting for cirrhotic versus malignant ascites. Surg Gynecol Obstet 161:204–208, 1985.PubMedGoogle Scholar
  42. 42.
    Rubenstein D, Mclnnes I, Dudley FJ: Morbidity and mortality after peritoneo-venous shunt surgery for refractory ascites. Gut 26:1070–1073, 1983.CrossRefGoogle Scholar
  43. 43.
    Greig PD, Langer BD, Blendis LM: Complications after peritoneovenous shunting for ascites. Am J Surg 139:125–131, 1980.PubMedCrossRefGoogle Scholar
  44. 44.
    Adler AJ, Feldman J, Friedman EA, Berlyne GM: Use of extracorporeal ascites dialysis in combined hepatic and renal failure. Nephron 30:31–35, 1982.PubMedCrossRefGoogle Scholar
  45. 45.
    Raju SF, Achord JL: The effects of dialytic ultrafiltration and peritoneal reinfusion in the management of diuretic resistant ascites. Am J Gastroenterol 79:308–312, 1984.PubMedGoogle Scholar
  46. 46.
    Lauer A, Saccaggi A, Ronco C, Belledonne M, Glabman S, Bosch JP: Continuous arteriovenous — hemofiltration in the critically ill patient: Clinical use and operational characteristics. Ann Intern Med 99:455–460, 1983.PubMedGoogle Scholar
  47. 47.
    Paganini E: Continuous replacement modalities in acute renal dysfunction. In: M Paganini, ed, Acute Continuous Renal Replacement Therapy. Martinus Nijhoff, Boston, 1986.CrossRefGoogle Scholar
  48. 48.
    Epstein M, Perez GO, Bedoya LA, Molina R: Continuous arteriovenous ultrafiltration in cirrhotic patients with ascites or renal failure. Int J Artif Organs, 9:253–256, 1986.PubMedGoogle Scholar
  49. 49.
    Epstein M: Hepatorenal syndrome. In: M Epstein, ed, The Kidney in Liver Disease, 3rd ed. Williams & Wilkins, Baltimore, pp 89–118, 1988.Google Scholar
  50. 50.
    Epstein M: Hepatorenal syndrome. In: JE Berk, ed, Gastroenterology, 4th ed. WB Saunders, Philadelphia, pp 3138–3149, 1985.Google Scholar
  51. 51.
    Flint A: A clinical report on hydro-peritoneum, based on an analysis of forty-six cases. Am J Med Sci 45:306–339, 1863.CrossRefGoogle Scholar
  52. 52.
    Epstein M: The Kidney in Liver Disease. In: SG, Massry, RB Glassock, eds, Textbook of Nephrology. Williams & Wilkins, Baltimore, pp 966–977, 1989.Google Scholar
  53. 53.
    Ritt DJ, Whelan G, Werner DJ, Eigenbrodt EH, Schenker S, Combes B: Acute hepatic necrosis with stupor or coma. Medicine 48:151–172, 1969PubMedCrossRefGoogle Scholar
  54. 54.
    Vesin P, Roberti A, Viguie RR: Defaillance renale fonctionnelle terminale chez des malades atteints de cancer du foie, primitif ou secondaire, Semin Hop Paris 26:1216–1220, 1965.Google Scholar
  55. 55.
    Epstein M, Oster JR, De Velasco RE: Hepatorenal syndrome following hemihepatectomy. Clin Nephrol 5:128–133, 1976.Google Scholar
  56. 56.
    Goldstein H, Boyle JD: Spontaneous recovery from the hepatorenal syndrome. Report of four cases. N Engl J Med 272:895–898, 1965.PubMedCrossRefGoogle Scholar
  57. 57.
    Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME: Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 280:1367–1371, 1969.PubMedCrossRefGoogle Scholar
  58. 58.
    Epstein M, Berk DP, Hollenberg NK, Chalmers TC, Abrams HL, Merrill JP: Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 49:175–185, 1970.PubMedCrossRefGoogle Scholar
  59. 59.
    Shear L, Kleinerman J, Gabuzda GJ: Renal failure in patients with cirrhosis of the liver. I. Clinical and pathologic characteristics. Am J Med 39:184–198, 1965.PubMedCrossRefGoogle Scholar
  60. 60.
    Dawson JL: The incidence of postoperative renal failure in obstructive jaundice. Br J Surg 52:663–665, 1965.PubMedCrossRefGoogle Scholar
  61. 61.
    Bismuth H, Kuntziger H, Corlette MB: Cholangitis with acute renal failure. Ann Surg 181:881–887, 1975.PubMedCrossRefGoogle Scholar
  62. 62.
    Oster JR, Epstein M, Ulano HB: Deterioration of renal function with demeclocycline administration. Curr Ther Res 20:794–801, 1976.PubMedGoogle Scholar
  63. 63.
    Carrilho F, Bosch J, Arroyo V, Mas A, Viver J, Rodes J: Renal failure associated with demeclocycline in cirrhosis. Ann Intern Med 87:195–197, 1977.PubMedGoogle Scholar
  64. 64.
    Arieff AI, Chidsey CA: Renal function in cirrhosis and the effects of prostaglandin A1. Am J Med 56:695–703, 1974.PubMedCrossRefGoogle Scholar
  65. 65.
    Zusman RM, Axelrod L, Tolkioff-Rubin N: The treatment of the hepatorenal syndrome with intrarenal administration of prostaglandin E 1. Prostaglandins 13:819–830, 1977.CrossRefGoogle Scholar
  66. 66.
    Bennett WM, Keffe E, Melnyk C, Mahler D, Rosch J, Porter GA: Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 135:964–971, 1975.PubMedCrossRefGoogle Scholar
  67. 67.
    Perez GO, Epstein M, Oster JR: Role of dialysis and ultrafiltration in the treatment of the renal complications of liver disease. In: M Epstein, ed, The Kidney in Liver Disease, 3rd ed. Williams & Wilkins, Baltimore, pp 613–624, 1988.Google Scholar
  68. 68.
    Ring-Larsen H, Clausen E, Ranek L: Peritoneal dialysis in hyponatremia due to liver failure. Scand J Gastroenterol 8:33–40, 1973.PubMedGoogle Scholar
  69. 69.
    Jacobson S, Bell B: Recognition and management of acute and chronic hepatic encephalopathy. Med Clin North Am 57:1569–1577, 1973.PubMedGoogle Scholar
  70. 70.
    Wilkinson SP, Weston MJ, Parsons V, Williams R: Dialysis in the treatment of renal failure in patients with liver disease. Clin Nephrol 8:287–292, 1977.PubMedGoogle Scholar
  71. 71.
    Klinger EL Jr, Cronin RJ: Renal failure in cirrhosis of the liver; Observations during intermittent hemodialysis. Abstracts Am Soc Artif Intern Organs:26, 1972.Google Scholar
  72. 72.
    Coratelli P, Passavanti G, Munno I, Fumarola D, Amerio A: New trends in hepatorenal syndrome. Kidney Int 17:S143-S147, 1985.Google Scholar
  73. 73.
    Ellis D, Avner ED: Renal failure and dialysis therapy in children with hepatic failure in the perioperative period of orthotopic liver transplantation. Clin Nephrol 25:295–303, 1986.PubMedGoogle Scholar
  74. 74.
    Perez GO, Oster JR, Epstein M: Role of dialysis and ultrafiltration in the treatment of renal complications of liver disease. In: M Epstein, ed, The Kidney in Liver Disease, 3rd ed. Williams & Wilkins, Baltimore, 1988.Google Scholar
  75. 75.
    Schroeder ET, Numann PJ, Chamberlain BE: Functional renal failure in cirrhosis. Recovery after portacaval shunt. Ann Intern Med 72:923–928, 1970.PubMedGoogle Scholar
  76. 76.
    Ariyan S, Sweeney T, Kerstein MD: The hepatorenal syndrome. Recovery after portacaval shunt. Ann Surg 181: 847–849, 1975.PubMedCrossRefGoogle Scholar
  77. 77.
    Kinney MJ, Schneider A, Wapnick S, Grosberg S, LeVeen HH: The ‘hepatorenal’ syndrome and refractory ascites: Successful therapy with the LeVeen-type peritoneal-venous shunt and valve. Nephron 23:228–232, 1979.PubMedCrossRefGoogle Scholar
  78. 78.
    Schroeder ET, Anderson GH, Smulyan H: Effect of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome. Kidney Int 15:54–61, 1979.PubMedCrossRefGoogle Scholar
  79. 79.
    Fullen WD: Hepatorenal syndrome: Reversal by peritoneovenous shunt. Surgery 82:337–341, 1977.PubMedGoogle Scholar
  80. 80.
    Schwartz ML, Vogel SB: Treatment of hepatorenal syndrome. Am J Surg 139:370–373, 1980.PubMedCrossRefGoogle Scholar
  81. 81.
    Linas SL, Schaefer JW, Moore EE, Good JT Jr, Giansiracusa R: Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int 30:736–740, 1986.PubMedCrossRefGoogle Scholar
  82. 82.
    Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI, Allen MJ, et al.: Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl Med 321:1632–1638, 1989.CrossRefGoogle Scholar
  83. 83.
    Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE: Recovery from “hepatorenal syndrome” after orthotopic liver transplantation. N Engl J Med 289:1155–1159, 1973.PubMedCrossRefGoogle Scholar
  84. 84.
    Starzl TE, VanThiel D, Tzakis AG, Iwatsuki S, Todo S, Marsh JW, Koneru B, et al.: Orthotopic liver transplantation for alcoholic cirrhosis. JAMA 260:2542–2544, 1988.PubMedCrossRefGoogle Scholar
  85. 85.
    Epstein M. Renal effects of head-out water immersion in man: Implications for an understanding of volume homeostasis. Physiol Rev 58:529–581, 1978.PubMedGoogle Scholar
  86. 86.
    Levinson R, Epstein M, Sackner MA, Begin R: Comparisons of the effects of water immersion and saline infusion on central hemodynamics in man. Clin Sci Mol Med 52:343–350, 1977.PubMedGoogle Scholar
  87. 87.
    Soulier JP, Jungers P, Zingraff J: Virus B hepatitis in hemodialysis centers. Adv Nephrol 6:383–405, 1976.Google Scholar
  88. 88.
    Kleinknecht D, Courouce AM, Delons S, et al.: Prevention of hepatitis B in hemodialysis patients using hepatitis B immunoglobulin: A controlled study. Clin Nephrol 8:373–376, 1977.PubMedGoogle Scholar
  89. 89.
    Marmion BP, Tonkin RW: Control of hepatitis in dialysis units. Br Med Bull 38:169–179, 1972.Google Scholar
  90. 90.
    Szmuness W, Prince AM, Grady GF, et al.: Hepatitis B infection: A point-prevalence study in 15 U.S. hemodialysis centers, JAMA 227:901–906, 1974.PubMedCrossRefGoogle Scholar
  91. 91.
    Decrease in the incidence of hepatitis in the dialysis units associated with prevention programmes. Public Health Laboratory Service Survey. Br Med J 4:751–754, 1974.Google Scholar
  92. 92.
    Kramer P, Brunner FP, Brynger H: Combined report on regular dialysis and transplantation in Europe, X, 1979. Read before the Proceedings of the European Dialysis and Transplant Association, Prague, June 11, 1980.Google Scholar
  93. 93.
    Najem GR, Louria DB, Thind IS, Lavenhar MA, Cocke DJ, Baskin SE, Miller AM, Frankel HJ, Notkin J, Jacobs MG, Weiner B: Control of hepatitis B infection: The role of surveillance and an isolation hemodialysis center. JAMA 245:153–157, 1981.PubMedCrossRefGoogle Scholar
  94. 94.
    Editorial. Hepatitis B vaccine. Lancet 2:1229–1230, 1980.Google Scholar
  95. 95.
    Stevens CE, Szmuness W, Goodman AI, Weseley SA, Fotino M: Hepatitis B vaccine. Immune responses in haemodialysis patients. Lancet 2:1211–1213, 1980.PubMedCrossRefGoogle Scholar
  96. 96.
    Deane N, Chalmers TC: Hepatitis and hemodialysis revisited. JAMA: 245:171–172, 1981.PubMedCrossRefGoogle Scholar
  97. 97.
    Eknoyan GA: Glomerular abnormalities in liver disease. In: M Epstein, ed, The Kidney in Liver Disease, 3rd ed. Williams & Wilkins, Baltimore, pp 154–181, 1988.Google Scholar
  98. 98.
    Takekoshi Y, Tanaka M, Miyakawa Y, Yoshizawa, Taka-hashi K, Mayumi M: Free “small” and IgG-associated “large” hepatitis Be antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis. N Engl J Med 300:814–819, 1979.PubMedCrossRefGoogle Scholar
  99. 99.
    Gocke DJ: Extrahepatic manifestations of viral hepatitis. Am J Med Sci 270:49–52, 1975.PubMedCrossRefGoogle Scholar
  100. 100.
    Combes B, Stastny P, Shorey J, Eigenbrodt EH, Barrera A, Hull AR, Carter NW: Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 2:234–237, 1971.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • Murray Epstein

There are no affiliations available

Personalised recommendations